Physician profile
Gary Baiocchi
NPI 1245200732
$460.50
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $90.30.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $94.55 | 2019-2020 | |
| Novo Nordisk INC | $42.47 | 2019 | |
| Abbvie INC. | $35.24 | 2019 | |
| Lilly USA, LLC | $31.23 | 2019-2020 | |
| Gilead Sciences, INC. | $28.34 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.57 | 2019 | |
| Amarin Pharma, INC. | $25.12 | 2019-2020 | |
| Pfizer INC. | $24.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.22 | 2020 | |
| Glaxosmithkline, LLC. | $20.93 | 2019 | |
| Hikma Pharmaceuticals USA | $15.99 | 2019 | |
| Endo Pharmaceuticals INC. | $15.55 | 2019 | |
| Astellas Pharma US INC | $15.18 | 2019 | |
| Shire North American Group INC | $15.13 | 2019 | |
| Allergan, INC. | $14.76 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.41 | 2020 | |
| Merck Sharp & Dohme LLC | $11.04 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Baiocchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.